Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction

Antibodies that block PD-L1/PD-1 immune checkpoints restore the activity of functionally-impaired antitumor T cells. These antibodies show unprecedented clinical benefit in various advanced cancers, particularly in melanoma. However, only a subset of cancer patients responds to current PD-L1/PD-1-bl...

Descripción completa

Detalles Bibliográficos
Autores principales: Hendriks, Djoke, He, Yuan, Koopmans, Iris, Wiersma, Valerie R., van Ginkel, Robert J., Samplonius, Douwe F., Helfrich, Wijnand, Bremer, Edwin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007955/
https://www.ncbi.nlm.nih.gov/pubmed/27622071
http://dx.doi.org/10.1080/2162402X.2016.1202390

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5007955/
https://www.ncbi.nlm.nih.gov/pubmed/27622071
http://dx.doi.org/10.1080/2162402X.2016.1202390

Ejemplares similares